I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional in Switzerland

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Oncology Cervical Cancer

Cervical Cancer

What's new

Sign up or login to unlock the full suite of MEDICALLY features
Nov 12 / Roche
Health Economic Impact Model of a Digital Health Solution
A health economic impact model assessing the benefits of a digital health solution, navify Cervical Screening. This digital health solution is designed to guide HCPs on local and standardized screening guidelines, offering a customized and centralized view of all patients under care, categorizes patients by next recommended action, and flags actions to prioritize tasks.
Oncology Cervical Cancer IPVC-2024

Sign up or login to unlock the full suite of MEDICALLY features
Apr 9 / Roche and Genentech
Tumor Microenvironment (TME) biomarkers of TIGIT and PD-L1 immune checkpoint blockade in Cervical Cancer: An Exploratory Biomarker Analysis from SKYSCRAPER-04 (SKY04) Study
Immune checkpoint blockade (ICB) is a new treatment option for advanced cervical cancer. SKYSCRAPER-04 (NCT04300647) explored the clinical activity of Tiragolumab (T, anti-TIGIT) plus atezolizumab (A, anti-PD-L1) dual immune checkpoint blockade (T+A) in patients (pts) with PD-L1+ cervical cancer. The goal of this biomarker exploratory sub-study was to characterize the tumor microenvironment of cervical cancer and its association with ICB clinical activity and Tiragolumab clinical outcome.
Oncology Cervical Cancer Ovarian Cancer AACR-2024

Sign up or login to unlock the full suite of MEDICALLY features
Mar 11 / Roche
Digital health potential for cervical cancer screening: Experience in Brazil
The urgent need for improved cervical cancer screening in Brazil is underscored by low adherence to screening protocols and the late detection of many cancers. This presentation delves into the challenges of the current screening framework and highlight a successful initiative in Indaiatuba, São Paulo, that leverages HPV-based screening in line with WHO and national guidelines. This approach has yielded promising results, notably in enhancing early detection, improving age compliance, and increasing the accuracy of cancer diagnoses. Furthermore, we present a digital health solution designed to streamline patient tracking, integrate lab results, and facilitate program management. Preliminary feedback indicates that this digital transformation could simplify processes and improve adherence to guidelines.
Oncology Cervical Cancer EUROGIN-2024

Sign up or login to unlock the full suite of MEDICALLY features
Mar 11 / Roche
HEALTH ECONOMIC IMPACT MODEL OF A DIGITAL HEALTH SOLUTION
A health economic impact model assessing the benefits of a digital health solution, navify Cervical Screening. This digital health solution is designed to guide HCPs on local and standardized screening guidelines, offering a customized and centralized view of all patients under care, categorizes patients by next recommended action, and flags actions to prioritize tasks.
Oncology Cervical Cancer EUROGIN-2024

Sign up or login to unlock the full suite of MEDICALLY features
Nov 5 / Roche and Genentech
Watch Efficacy and safety results from SKYSCRAPER-04: An open-label randomized phase 2 trial of tiragolumab plus atezolizumab for PD-L1-positive recurrent cervical cancer
Plenary presentation.
Oncology Cervical Cancer IGCS-2023

Sign up or login to unlock the full suite of MEDICALLY features
Nov 5 / Roche and Genentech
A Novel Solution to Reduce the Disease Burden for Breast and Cervical Cancer in Ghana: A Model for Low-Resource Countries
A new, multidisciplinary, collaborative approach was undertaken with Jhpiego, Ghana Health Service and Roche to support Ghana Health Service in establishing a multi-sectoral technical working group to develop the necessary demonstrations/proof of concept, guidelines, training packages and training-of-trainers to roll-out integrated women’s breast and cervical cancer care. As a first step, a cross sectional needs assessment was conducted to understand awareness and availability of screening services for breast and cervical cancers.
Oncology Breast Cancer Cervical Cancer AORTIC-2023

Ask a question or share feedback

Get in touch

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.